Bull Market in Biotech
The biotech sector has weathered the current corrective cycle and shown strong relative strength versus the broader market breakdown.
The S&P Biotechnology index stalled its upside progress in February, but failed to break down and instead the index formed a bullish consolidation pattern. When a sector bucks the general market trend and moves against the grain it generally gets our attention as technicians. The resiliency in the biotechnology sector suggests to us that there is a bullish catalyst at work in the sector and we could see some interesting strength reemerge from the group once the bulls take back control of the broader market action....382 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.
